Clinical Trials Details

NRG-GI004/S1610 COMMIT (Colon)

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study

Objective

A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.

Clinical Trial Categories

  • Cancers and Other Neoplasms